Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

PI-88 under development for cardiovascular indication; Progen enters strategic alliance

June 2, 2000

Orally bioavailable thrombin inhibitors designed at Pfizer

June 1, 2000

Antiplatelet effects reported for new cell adhesion inhibitors from Takeda

June 1, 2000

Angiomax approvable for use as anticoagulant

May 26, 2000

Lilly prepares potent and orally active thrombin inhibitors

May 25, 2000

Neutralase studied in percutaneous coronary intervention trial

May 23, 2000

FDA denies approval for Refludan in acute coronary syndrome

May 19, 2000

Genzyme Transgenics and Genzyme General receive orphan drug designation

May 18, 2000

Eryloside F: a new thrombin receptor antagonist produced by a marine sponge

May 17, 2000

Glaxo Wellcome reveals recent findings in its thrombin inhibitor program

May 17, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...